CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Phase 1/2 Unknown 10 enrolled PersonGen BioTherapeutics (Suzhou) Co., Ltd. Hefei Binhu Hospital · collab The First People's Hospital of Hefei · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical trial is to study genetically engineered NK92 cell therapy in treating patients with CD33 positive acute myeloid leukemias that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to further chemotherapy.

Timeline

Start: 2016-10
Primary completion: 2017-09
Completion: 2018-09

Publications

Del Zotto G, Marcenaro E, Vacca P, Sivori S, Pende D, Della Chiesa M, Moretta F, Ingegnere T, Mingari MC, Moretta A, Moretta L. Markers and function of human NK cells in normal and pathological conditions. Cytometry B Clin Cytom. 2017 Mar;92(2):100-114. doi: 10.1002/cyto.b.21508. Epub 2017 Feb 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	anti-CD33 CAR NK cells	Cell therapy	—	—

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Summary

Timeline

Publications

Drugs

Indications